Embolization Particle Market –
Regional Insights
On the basis of geography, the
global Embolization
Particle Market is segmented into North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa. North America would be dominant region
in the global embolization particle market in 2017. This is owing to the strong
economic condition, huge expansion of healthcare domain, and increasing focus
of research institutions on modernizing technology for new and advanced
diagnosis and treatment methods. Moreover, unique hospital infrastructures, and
availability of skilled healthcare professionals is further aiding growth of
the market.
On the other hand, Asia Pacific
is expected to witness significant growth in embolization particle market
during the forecast period, owing to increasing patient population (mainly
cancer) in emerging economies such as India. For instance, according to Indian
Council Medical Research (ICMR), it is expected that over 17.3 lakh new cancer
cases and over 8.8 lakh deaths will occur in India due to cancer by 2020.
Moreover, growing focus by government on enhancing healthcare facilities and
booming medical tourism is expected to boost growth of the embolization
particle market in this region.
Embolization is a minimally
invasive therapy in which an embolus is injected to stop bleeding or to cut off
the supply of blood to a tumor in order to shrink it for preparation of its
removal. Embolization is used in various interventional radiology procedures.
In this procedure, an interventional radiologist uses image guidance to insert
the catheter into a primary artery and advance it to vessel leading to a tumor
or other part where the blood supply needs to be blocked. Embolization is an
option for some patients with tumors that cannot be removed by surgery. It can
be used for tumors that are usually larger than 5 cm thickness and cannot be
removed by ablation. This procedure is used to treat various types of cancerous
tumors, hemorrhages, along with the management of malignant hypertension caused
by renal failure.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2374
Embolization procedure uses various
types of embolization particles such as radioembolization spheres,
microspheres, drug eluting beads, PVA particles, gelfoam particles, and other
particles. These particles are used in different procedures such as liver
cancer, metastatic cancer in the liver, kidney cancer, neuroendocrine tumors,
uterine fibroids, and aneurysms. These particles are highly used in the
treatment of various types of cancers whose prevalence has been increasing
across the globe.
Embolization Particle Market -
Market Dynamics
The market for embolization
particle is driven by factors such as increasing prevalence of various types of
cancer.
Embolization particles are the
crucial product used in the treatment of malignancies such as cancer,
peripheral diseases, and others. Rising prevalence of cancer globally, has
supported growth of the embolization particle market. According to World Health
Organization (WHO), cancer is the second prominent cause of death across the
globe, and around 9.6 million deaths occurred due to cancer in 2018. Moreover,
as per the Cancer Research UK, over 17 million new cases were estimated to
occur in year 2018 around the globe. The burden of cancer is increasing rapidly
in the U.S. with the incidence of 439.2 per 100,000 men and women per year as
according to National Cancer Institute (2015).
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/embolization-particle-market-2374
Moreover, major players are
constantly introducing technologically advanced products with improved
efficiency that supports growth of the embolization particle market. For
instance, in 2017, Sirtex introduced SIR-Spheres Y-90 resin microspheres, which
serves as first-line treatment for patients with liver metastases from
right-sided primary colon cancer. In 2016, UK National Institute for Health and
Care Excellence (NICE) issued a new update stating that National Health Service
(NHS) doctors and commissioners may consider Sirtex’s SIR-Spheres Y-90 resin
microspheres as an alternative to standard therapy with trans-arterial
chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable
primary liver cancer.
However, lesser number of
interventional neuroradiologists and interventional neuroradiology (INR) labs
across the globe and stringent regulations for embolization particle approvals
are some of the major factors restraining growth of the global embolization
particle market.
Embolization Particle Market –
Competitive Landscape
Major players operating in the
embolization particle markets include, Abbott Laboratories, Boston Scientific
Corporation, BTG plc, Cook Medical, Inc., Edwards Lifesciences, Johnson &
Johnson, Pfizer, Inc., Sirtex Medical Limited, St. Jude Medical, Inc., and
Terumo Corporation.
Key players are focusing on
mergers & acquisitions and new product launches in order to retain dominant
position in the market. For instance, in November 2018, Boston Scientific
announced it plans to acquire BTG plc is a global healthcare company focused on
interventional medicine. This will help the company to develop and
commercialize products used in minimally-invasive procedures targeting cancer
and vascular diseases
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2374
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment